mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced poor prognostic renal cell carcinoma. Consistent data have recently shown the important role of the PI3K/AKT/mTOR signalling pathway in the regulation of crucial metabolic and mitotic functions of cancer cells and endothelial cells allowing a better understanding of the role of mTOR in controlling cancer cell proliferation and survival as well as tumour angiogenesis. As a result, rapamycin derivatives (rapalogues) that block mTOR/Raptor complex 1 were shown to exert direct antiproliferative effects against endometrial cancers, in which cancer cells frequently lose PTEN function as well as mantle cell lymphomas, in which cancer cell proliferation appears to be driven primarily by cyclin D1 overexpression. The overall antitumour effects of rapalogues in renal cell carcinoma appear to be more complex with tumour growth inhibition resulting from direct G1/S cell cycle blockage and/or apoptotic effects in carcinoma cells along with the inhibition of downstream signalling of the HIF1alpha-induced VEGF/VEGFR autocrine loop in endothelial cells shutting down the maintenance of tumour angiogenesis. Despite extensive cognitive researches, it is difficult to appraise which of those mechanisms is predominant in patients. This review focuses on mechanisms of action of rapalogues focusing on antitumour effects in patients with renal cell carcinoma.
Le Tourneau
C
C
Department of Medical Oncology, APHP and INSERM U728, RayLab, Beaujon University Hospital, Clichy, France.
Faivre
S
S
Serova
M
M
Raymond
E
E
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes; D011506:Proteins; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D014157:Transcription Factors / Q000187:drug effects / Q000378:metabolism*
D000970:Antineoplastic Agents; D046912:Multiprotein Complexes; D011506:Proteins; D014157:Transcription Factors; C401859:temsirolimus; D000076222:Mechanistic Target of Rapamycin Complex 1; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31
17671154
Nat Rev Drug Discov. 2007 Sep;6(9):734-45
17690708
J Clin Oncol. 2005 Aug 10;23(23):5347-56
15983389
J Clin Pharmacol. 2007 Nov;47(11):1430-9
17913896
Genes Dev. 2005 Sep 1;19(17):2054-65
16107612
Ann Oncol. 2005 Jun;16(6):928-33
15851405
J Clin Oncol. 2004 Jun 15;22(12):2336-47
15136596
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Nat Rev Drug Discov. 2006 Aug;5(8):671-88
16883305
Br J Cancer. 2008 Mar 11;98(5):923-30
18319715
Mod Pathol. 2002 May;15(5):479-85
12011252
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
J Clin Oncol. 2008 Apr 1;26(10):1596-602
18332467
J Biol Chem. 2002 Apr 26;277(17):15162-70
11859074
Int J Cancer. 2002 May 1;99(1):53-7
11948491
J Urol. 2005 May;173(5):1496-501
15821467
Am J Obstet Gynecol. 2007 Mar;196(3):247.e1-5
17346540
J Clin Oncol. 2008 Apr 1;26(10):1603-10
18332469
Cancer Res. 1999 Aug 1;59(15):3581-7
10446965
J Clin Oncol. 2007 Sep 1;25(25):3958-64
17761980
Nat Med. 2002 Feb;8(2):128-35
11821896
Clin Cancer Res. 2006 Oct 1;12(19):5755-63
17020981
Apoptosis. 2004 Nov;9(6):797-805
15505422
Clin Cancer Res. 2001 Apr;7(4):892-5
11309338
J Clin Oncol. 2008 Jan 20;26(3):361-7
18202410
Chest. 2008 Feb;133(2):528-38
18252919
Oncol Rep. 2005 Aug;14(2):389-92
16012720
Nat Med. 2006 Jan;12(1):122-7
16341243
Ther Clin Risk Manag. 2007 Jun;3(2):341-8
18360643
N Engl J Med. 2007 Jan 11;356(2):125-34
17215530
J Clin Oncol. 2004 Mar 1;22(5):909-18
14990647
Clin Cancer Res. 2007 Dec 15;13(24):7401-6
18094423
J Clin Oncol. 2008 Apr 1;26(10):1588-95
18332470
J Clin Oncol. 2006 Jan 1;24(1):25-35
16314617